X

Trial Profile

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto Respimat [ELLACTO]

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olodaterol/tiotropium bromide (Primary)
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Acronyms ELLACTO
Sponsors Boehringer Ingelheim

Most Recent Events

10 Apr 2019 Status changed from active, no longer recruiting to completed.
04 Mar 2019 Planned End Date changed from 22 Feb 2019 to 8 Mar 2019.
04 Jan 2019 Planned End Date changed from 31 Dec 2018 to 22 Feb 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com